Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

First-in-Class Pipeline Could Address Unmet Needs in RA Treatment Space

By Fiona Chisolm, Analyst, GBI Research | August 18, 2016

The rheumatoid arthritis market is highly lucrative and significant advances in the understanding of the disease have greatly improved treatment options for a large number of patients over the past two decades. However, serious unmet needs remain, and there are still many opportunities for future drug developments, particularly for first-in-class innovation, according to business intelligence provider GBI Research.

The company’s latest report states that rheumatoid arthritis remains an incurable condition with no therapeutics that directly act to restore bone content and reduce cartilage degradation. Safety, often concerning elevated infection as a result of immunosuppression, remains a concern, while many patients respond inadequately or eventually develop resistance to first- and second-line therapies. In addition, biologics require either intravenous or subcutaneous administration, which is often inconvenient and painful for patients.

The current disease pipeline is relatively large, containing 454 products. While the proportion of first-in-class products in the pipeline is marginally lower than the industry average, it contains many first-in-class targets that have the potential to lead to therapeutic advances. In particular, there is a higher proportion and diversity of first-in-class molecular targets in the early development stages than in the clinical trial development stages.

This is an encouraging trend, revealing sustained research and development in rheumatoid arthritis. Nonetheless, limited first-in-class innovation at the later development stages suggests that the therapeutic landscape will continue to be dominated by currently marketed products in the near future.

GBI Research’s report also states that in terms of types of first-in-class products in the pipeline, cytokine and cytokine receptors, as well as protein kinases, largely dominate. Most first-in-class products targeting cytokines and their receptors are biologic therapies, and target a range of mediators that underlie inflammatory and adaptive immune responses in rheumatoid arthritis.

First-in-class products targeting protein kinases are predominantly orally administered small molecules and will be well-positioned to address the current unmet need for improved ease and convenience of drug delivery.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE